Considerations in the treatment of elderly patients with psoriasis and atopic dermatitis using biologics and small-molecule drugs
- VernacularTitle:老年银屑病和特应性皮炎患者生物制剂及小分子药物治疗中应注意的问题
- Author:
Bo WANG
1
;
Jie ZHENG
Author Information
- Publication Type:Journal Article
- Keywords: Psoriasis; Dermatitis, atopic; Aged; Therapy; Biological agents; Small-molecule drugs; Prognosis; Drug-related side effects and adverse reactions
- From: Chinese Journal of Dermatology 2025;58(1):72-75
- CountryChina
- Language:Chinese
- Abstract: Psoriasis and atopic dermatitis are common inflammatory skin diseases in the elderly, characterized by chronic inflammation and immune imbalance, making their management challenging. The emergence of biologics and small-molecule drugs has revolutionized the treatment of psoriasis and atopic dermatitis by markedly improving efficacy and safety compared to conventional therapies. However, their application in elderly patients poses challenges. Due to the presence of comorbidities in elderly patients, accurate diagnosis is critical by differentiating psoriasis and atopic dermatitis from other skin diseases, with an emphasis on the auxiliary role of histopathological examination and laboratory tests. In the treatment of elderly patients with psoriasis and atopic dermatitis using biologics and small-molecule drugs, comprehensive treatment should address both skin symptoms and systemic health, with careful drug selection tailored to individuals. Safety monitoring, particularly vigilance for risks such as infections, lipid abnormalities, and cardiovascular events, is essential during treatment. Education efforts are needed to improve patient knowledge and acceptance of biologics and small molecule drugs. Future research should focus on accumulating clinical data in elderly populations to provide a basis for precision treatment of elderly patients with psoriasis and atopic dermatitis.
